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aBstract
Purpose: Information about the 
safety of herbal medicine often 
comes from case reports published in 
the medical literature, thus necessi-
tating good quality reporting of these 
adverse events. The purpose of this 
study was to perform a systematic 
review of the comprehensiveness of 
reporting of published case reports of 
adverse events associated with herb 
use in the pediatric population. 
Methods: Electronic literature 
search included 7 databases and a 
manual search of retrieved articles 
from inception through 2010. We 
included published case reports and 
case series that reported an adverse 
event associated with exposure to an 
herbal product by children under the 
age of 18 years old. We used descrip-
tive statistics. Based on the 
International Society of 
Epidemiology’s “Guidelines for 
Submitting Adverse Events Reports 
for Publication,” we developed and 
assigned a guideline adherence score 
(0-17) to each case report.
Results: Ninety-six unique journal 
papers were identified and represent-
ed 128 cases. Of the 128 cases, 37% 
occurred in children under 2 years 
old, 38% between the ages of 2 and 8 
years old, and 23% between the ages 
of 9 and 18 years old. Twenty-nine 
percent of cases were the result of an 
intentional ingestion while 36% 
were from an unintentional inges-
tion. Fifty-two percent of cases docu-
mented the Latin binomial of the 
herb ingredients; 41% documented 
plant part. Thirty-two percent of the 
cases reported laboratory testing of 
the herb, 20% documented the man-
ufacturer of the product, and 22% 
percent included an assessment of 
the potential concomitant therapies 
that could have been influential in 
the adverse events. Mean guideline 
adherence score was 12.5 (range 6-17).
Conclusions: There is considerable 
need for improvement in reporting 
adverse events in children following 
herb use. Without better quality 
reporting, adverse event reports can-
not be interpreted reliably and do not 
contribute in a meaningful way to 
guiding recommendations for 
medicinal herb use. 
摘要
目的：关于草药安全性的信息往
往来自医疗文献中发布的病例报
告，因而对这些不良事件进行高
质量的报告极为必要。本研究旨
在针对已发布的病例报告（对该
群体（儿童）使用草药相关的不
良事件的报告），就其全面性进
行系统性的审查。
方法：包括对 7 个数据库进行电
子文献搜索和对从 2010 年以来检
索到的文章进行手动搜索。我们
纳入了已发布的病例报告和病例
系列，它们报告了与年龄不满 18 
周岁的儿童接触草药制品有关的
不良事件。我们使用了描述性的
统计数据。根据国际流行病学会 
“针对准备对外发布的不良事件
报告的提交指导方针”，我们向
每个病例报告制定并分配了指导
方针的遵从性得分 (0-17)。
结果：96 篇独一无二的期刊论文
确认并展示了128 个病例。在这 
128 个病例当中，37% 发生在不满 
2 周岁的儿童当中，38% 介于 2 
到 8 岁之间，23% 介于 9 到 18 
岁之间。29% 的病例是有意识食物
摄入的结果，而 36% 来自无意识
的食物摄入。52% 的病例记录了草
药成分的拉丁二项式；41% 记录了
植物部分。32% 的病例报告了对草
药的实验室测试，20% 记录了产品
的制造商，22% 纳入了可能对不良
事件有影响的潜在伴随治疗的评
估。平均指导方针遵从性得分为 
12.5（范围 6-17）。
结论：针对儿童使用草药后的不
良事件报告有很大的改进必要。
如果没有质量更好的报告，不良
事件报告将无法可靠地解释且不
会以有意义的方式对草药的使用
提供指导性建议。
sINOpsIs
Propósito: La información sobre la 
seguridad de los productos fitotera-
péuticos procede con frecuencia de 
informes de caso incluidos en publi-
caciones médicas, por lo que se 
necesita una notificación de buena 
calidad de estos acontecimientos 
adversos. El propósito de este estu-
dio era realizar una revisión 
sistemática de la exhaustividad de 
notificación de los informes de caso 
publicados sobre acontecimientos 
adversos asociados con el uso de 
productos fitoterapéuticos en la 
población pediátrica. 
Métodos: La búsqueda de publica-
ciones electrónicas incluyó siete 
bases de datos y una búsqueda man-
ual de los artículos recuperados 
desde el inicio hasta 2010. Se incluy-
eron informes de caso publicados y 
series de casos que notificaban un 
acontecimiento adverso asociado 
con la exposición a un producto fito-
terapéutico de niños de menos de 18 
años. Se utilizó la estadística descrip-
www.gahmj.com • March 2013 • Volume 2, Number 2 47review
SYSTEMATIC REVIEW OF PEDIATRIC HERBAL ADVERSE EVENTS
INtrOdUctION
In 2007, an estimated 12% of US children used 
complementary and alternative medicine (CAM), and 
5% of children used biologically based therapies includ-
ing herbs and dietary supplements.1 Little is known 
about pediatric herbal safety and whether details of 
herbal adverse events (AEs) are comprehensively report-
ed in the literature.
Definitions vary, but in general an AE is an unin-
tended, undesired, or harmful effect associated with the 
use of a medication, intervention, or dietary supple-
ment.2 In terms of models of herbal adverse event sur-
veillance, there are many ways that adverse event reports 
(AERs) are collected in children including case reports in 
journals, poison control centers, and other state and 
national government organizations (eg, Medwatch). For 
example, the California Poison Control Centers reported 
that of 828 dietary supplement–related AE exposure 
reports, more than half were among children.3
AERs are also reported in the indexed medical liter-
ature. Case reports often come in the form of letters to 
the editors, brief reports, or case reports from clinicians 
who can comment on the presentation of the patient 
and the treatment plan that was followed to address the 
event.4 Case reports may be a useful source of informa-
tion about herbs for clinicians but only if the informa-
tion reported is sufficient in quality and content to allow 
for meaningful adjudication. 
In this article, we review case reports of pediatric 
AEs found in English language medical journals related 
to children’s herb use and assess the quality of the AERs 
using a scale based on the International Society of 
Epidemiology’s (ISE) “Guidelines for Submitting 
Adverse Events Reports for Publication.”4 While we do 
not have enough information to assess causality related 
to AEs, we can investigate whether case reports docu-
ment the critical information about the AEs. We hypoth-
esized that there would be a wide variety of adherence to 
the ISE’s guidelines in the documentation of AERs 
described in case reports and that the overall documen-
tation of the case reports would be poor. While we are 
not suggesting new guidelines for reporting, we hope to 
highlight the importance of accurate and complete doc-
umentation and reporting of AEs related to herb use. 
mEthOds
data sources
We systematically searched seven databases: 
Medline, Embase, Toxline, DART, CINAHL, Cochrane 
CENTRAL, and Global Health from inception through 
2010 using Medical Subject Headings (MeSH) terms 
such as herb, herbal medicine, phytotherapy, medicinal herb, 
plant extract, natural health products (NHPs), pediatrics, 
case reports, case series, and safety (see Appendix 1 for all 
MeSH terms used in the search strategy). Titles and 
abstracts of identified references were screened by two 
independent reviewers. Full publications of potentially 
relevant articles were obtained for further examination. 
We checked the references of each included article for 
additional reports. 
study selection 
We included peer-reviewed case reports/series pub-
lished through 2010 that described an AE occurring in 
newborns, infants, children, and youth from birth to age 
18. Case reports were of medicinal herbal products taken 
by any route (eg, oral, topical) by either a child or preg-
nant woman whose newborn was affected by the prod-
uct. We did not include non-herb dietary supplements 
(eg, glucosamine, coenzyme Q10). Dissertations, 
ab stracts, and non-English publications also were 
excluded. We also excluded randomized controlled tri-
als as the purpose of this study was to analyze case 
reports and case series.
data Extraction 
The following data were independently double-
extracted into a standardized database: patient demo-
graphics, medical history, details of case (eg, how prod-
uct exposure occurred, medical tests, treatment, and 
outcome), and product details (eg, name, contents, man-
ufacturer). The main adverse event was characterized 
tiva. Con base en las «Pautas para el 
envío de informes de acontecimien-
tos adversos para su publicación» 
(Guidelines for Submitting Adverse 
Events Reports for Publication) de la 
Sociedad Internacional de 
Epidemiología (International 
Society of Epidemiology), se elaboró 
y asignó una puntuación de segui-
miento de las pautas (de 0 a 17) a 
cada informe de caso.
Resultados: Se identificaron 96 
publicaciones únicas que represent-
aban 128 casos. De ellos, el 37 % se 
produjo en niños menores de 2 años 
de edad, el 38 % en niños de entre 2 
y 8 años de edad, y el 23 % entre las 
edades de 9 y 18 años. El 29 % de los 
casos fue resultado de la ingesta 
intencional, mientras que el 36 % lo 
fue de una ingesta no intencionada. 
El 52 % de los casos documentaba el 
nombre científico binominal en 
latín de los ingredientes del produc-
to fitoterapéutico y el 41 % docu-
mentaba la parte de la planta. El 32 
% de los casos notificaba pruebas de 
laboratorio del producto fitotera-
péutico, el 20 % documentaba su 
fabricante y el 22 % incluía una 
evaluación de los posibles trata-
mientos concomitantes que podían 
haber influido en los acontecimien-
tos adversos. La puntuación media 
de seguimiento de las pautas era de 
12,5 (rango de 6 a 17).
Conclusiones: Resulta bastante 
necesario mejorar la notificación 
de acontecimientos adversos en los 
niños después del uso de productos 
fitoterapéuticos. Sin notificaciones 
de mejor calidad, los informes de 
acontecimientos adversos no 
pueden interpretarse de manera 
fiable ni contribuyen de forma sig-
nificativa a las recomendaciones 
de guía para el uso de productos 
fitoterapéuticos. 
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according to the primary symptom. If there were differ-
ences between reviewer categorization, we resolved it by 
discussion and consensus. 
To assess quality of documentation, we developed a 
17-point scale by adapting recommendations from the 
ISE’s “Guidelines for Submitting Adverse Events Reports 
for Publication.”4 These guidelines were selected because 
they specifically take into account reporting herbal 
medicine case reports and the nuances unique to such 
reports such as the Latin binomial name of the herb and 
the generic or proprietary name of the herb. Information 
required for inclusion into our adherence scale was 
derived from the guidelines.4 One point was allocated for 
reporting each of the following information: patient age 
and sex, description of the health condition being treated 
with the suspected herb, medical history related to the 
adverse event, physical exam, outcome of the patient 
(presence or absence of death, life-threatening circum-
stances, hospitalization or prolonged hospitalization, or 
significant disability), the Latin binomial name of herb 
ingredient(s), the generic or proprietary name of herb, 
the plant part(s) of the herb, the type of preparation (eg, 
crude herb or extract, pill/capsule, powder), manufactur-
er, dosage of the herb, duration of therapy, assessment of 
potential contribution of concomitant therapies, descrip-
tion of AE and its severity compared with established 
definitions and outcome of AE, and if the report included 
a discussion. The discussion must address causality, tim-
ing, and the presented report’s consideration of previ-
ously published adverse events. To our knowledge, this 
scale has not been validated in previous studies.
Based on the ISE’s guidelines, our adapted adher-
ence scale represents the most basic level of the informa-
tion necessary for appropriate case presentation of an AE 
related to pediatric herb use. Interpretation of the scale 
was done on each case report. 
statistical analysis
We used descriptive statistics using SAS software 
(version 9.1, SAS Institute Cary, North Carolina). To 
assess for significant factors associated with studies with 
higher adherence scores, we used Poisson regression 
analysis. We categorized variables as follows: age (not 
documented, 0-23 months, 2-3 years, 4-8 years, 9-13 
years, 14-18 years); race (not documented, Non-Hispanic 
white, Hispanic, African American, Asian, other); gen-
der; time of exposure (postnatal or prenatal exposure); 
main adverse event reported; route of administration 
(not specified, intentional oral ingestion, unintentional 
oral ingestion, intentional topical application, uninten-
tional topical exposure, multiple modes); contaminated 
or adulterated products; lab analysis of herb; lab analysis 
of patient; exposure to heavy metals; disposition of 
patient (not documented, resolution of symptoms fol-
lowing hospitalization, resolution of symptoms with 
medications or outpatient therapy, death, disability, 
organ transplantation); location of case; year of publica-
tion (before 1980, 1981-1990, 1991-2000, and 2001-2010). 
Year of publication was further analyzed as cases pub-
lished before 2007 and after 2007. Journals were catego-
rized as adult or pediatric to assess if journals specializ-
ing on children would yield a higher adherence score. 
rEsULts
The searches identified 12 386 references. Initial 
screening of titles and abstracts removed 12 170 refer-
ences. Full text of the remaining 216 references were 
obtained and assessed for inclusion. Figure 1 demon-
strates our search strategy. 
There were 96 unique articles representing 128 
cases included in the analysis (Appendix 2). Table 1 
describes the characteristics of the included cases. More 
than 50% of cases occurred in children 3 years of age or 
less. In 8% of the cases (n = 10), exposure occurred 
through maternal transmission to the fetus. Some moth-
ers used herbs for labor and feeding purposes; however, 
many studies were unclear about duration of herbal use. 
The most frequent herbs or herbal combinations men-
tioned in case reports were eucalyptus (n = 12), camphor 
(n = 10), fennel (n = 6), jin bu huan (n = 6), swanuri marili 
(n = 6), kharchos suneli (n = 6), tea tree (n = 5), lavender 
(n = 4), blue cohosh (n = 3), buckthorn (n = 3), liquorice 
(n = 3), and garlic (n = 3). While many cases reported mul-
tiple symptoms, there were a wide variety and severity of 
symptoms presented (Table 1). The most common (35% 
of the cases) symptoms were neurological AEs (eg, sei-
zures). Fourteen percent of the cases (n = 18) revealed 
gastrointestinal disturbances (eg, nausea, vomiting). 
There was great diversity among route of exposure 
among the pediatric population discussed. Twenty-nine 
percent of cases were the result of an intentional inges-
tion, and 36% were from an unintentional ingestion. In 
17% of the cases, the reactive agent was topically applied 
either as a lotion or bath solution. There were also cases 
where the child used a product that was contaminated 
(5%, n = 6) or adulterated (2%, n = 2) associated with an 
AE. In 7% of the studies (n = 9), the AE was fatal to the 
individual; however, specific causality was not assessed. 
12 386 records identified 
through database searching 
216 full-text articles 
assessed for eligibility 
96 articles included 
128 included cases
12 170 records excluded 
120 studies excluded:
38 duplicate articles
29 not pediatric
22 herb used as recreational drug 
18 non-English
8 not a medicinal herb
3 not case reports
2 no adverse event 
Figure 1 Flow of studies through review.
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Seventy percent reported that the patient had a com-
plete resolution of symptoms following hospitalization. 
There was a resolution of symptoms with medication or 
outpatient therapy in 14% of the cases. 
Table 2 includes the 17 items based on the AER 
guidelines and the number of AERs that reflected 
adherence to this item. Fifty-two percent of studies 
documented the Latin binomial of the herb ingredi-
ents. Documentation of the plant part was evident in 
41% of the cases, and 94% documented the type of 
preparation of the herbal medicine. Thirty-two per-
cent of the cases reported laboratory testing of the 
herb, and 22% documented the manufacturer of the 
product. Dosage information revealed that 59% of 
cases reported the amount of herb taken by the patient. 
Duration of herb use was documented in 92% of the 
cases, and 44% of reports included the duration of 
herb use before the AE. Twenty-two percent included 
an assessment of the potential concomitant therapies 
that could have been influential in the AEs. 
Figure 2 displays the distribution of adherence 
scores for AEs. Adherence scores ranged from 6 to 17, the 
highest attainable score. The mean for all scores was 12.5 
(SD 1.8) There was no association between a higher score 
and whether the case report was documented in an adult 
journal or a pediatric journal (P = .87). There was no cor-
relation between a higher score and the year of publica-
tion (P = .51). Table 3 lists several examples of cases that 
met or almost met all the AER guidelines (15 to 17 
points).5-23 This table does not address causality but pro-
vides examples of case reports with good documentation.
dIscUssION 
Upon review of the literature, we found a wide 
spectrum of AERs with poor documentation related to 
herb use in children. In our analysis of 128 AERs, the 
average adherence score for all cases was 12.5 with the 
highest attainable score being 17. One cannot deter-
mine if an herbal product caused an AE if all the infor-
mation about the patient and the product are not 
table 1 General Description of Adverse Events (N = 128 Individual Cases)
category        N (%) 
age
Not documented 
0-23 mo
2-3 y 
4-8 y 
9-13 y 
14-18 y
1 (1)
48 (37)
25 (20)
23 (18)
14 (11)
17 (13)
race
Not documented 
Non-Hispanic white 
Hispanic 
African American 
Asian 
Other
80 (63) 
14 (11) 
12 (9)
2 (2) 
8 (6)
12 (9)
Gender
Male
Female
Not documented
55 (43)
55 (43)
18 (14) 
time of Exposure 
Prenatal 
Postnatal 
10 (8)
118 (92)
main adverse Event reporteda
Neurological (seizures, central nervous system depression, lethargy) 
Gastrointestinal (nausea, vomiting, diarrhea)
Liver toxicity and jaundice 
Cardiovascular/hematological (hypertension, blood toxicity)
Dermatological (rash, burns)
Respiratory (coughing, respiratory depression) 
Endocrine/reproductive/renal 
Cyanosis
Neonatal withdrawal (drugs or alcohol) 
Anaphylactic shock 
45 (35) 
18 (14)
14 (11) 
13 (10) 
12 (9)
9 (7)
8 (6) 
6 (5) 
2 (2) 
1 (1) 
route of administration 
Unintentional oral ingestion
Intentional oral ingestion 
Topically applied 
Multiple modes 
Not specified 
Unintentional exposure to skin 
46 (36)
37 (29)
22 (17)
2 (2)
2 (2)
1 (1)
contaminated or adulterated products
Contaminated products reported in cases
Adulterated products reported in cases
6 (5) 
2 (2)
documentation of testing herb in laboratory 41 (32)
documentation of laboratory work on patient 102 (80)
documentation of Exposure to heavy metals
Lead 
Arsenic
None
9 (7) 
2 (2) 
117 (91)
disposition 
Resolution of symptoms following hospitalization
Resolution of symptoms with medications or outpatient therapy
Death
Disability
Organ transplantation
Not documented
90 (70)
18 (14)
9 (7)
7 (6)
3 (2) 
1 (1) 
Location of case 
United States
Europe (continental) 
Asia
Australia
Great Britain
India
Canada
Africa
Central America 
Unknown
40 (31) 
26 (20)
21 (17)
14 (11)
9 (7)
6 (5)
5 (4)
3 (2)
3 (2)
1(1)
a This reflects the main clinical adverse event in case. Cases may have other symptoms reported. 
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Figure 2 Number of adverse events by adherence score. 
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known or reported. Our results highlight the need for 
better documentation of AERs in children following 
herbal product use. In addition to the ISE’s guidelines, 
there are other models of developing standardized 
reporting in peer-reviewed journals.24,25 
The widespread use of herbal products among chil-
dren necessitates the exploration into the safety of these 
herbs. While randomized controlled trials are the mod-
ern-day gold standard for evaluating efficacy, the sample 
size is often too small to detect rare but serious harms, and 
the length of follow-up is often too short to detect harms 
after prolonged exposure.25 In contrast, case re ports can 
be good sources of information about AEs, especially for 
new/emerging harms, those that are rare, and those that 
occur after prolonged use. Case reports, however, cannot 
determine the incidence of specific AEs. They may only 
highlight one or several reports of an occurrence. In order 
to provide an accurate signal of harm, these reports must 
clarify certain details about the AE. 
Like drug AERs, herbal AERs often require additional 
information, including details of the herbal product (eg, 
dose/amount taken and duration, exact names of ingredi-
ents as listed on the product label), de-challenge/rechal-
lenge information, and patient characteristics. As noted in 
the reports on products containing ephedra, insufficiently 
documented case reports hamper informed judgment in 
evaluating relationships between AERs and a product.26 
For example, the person filing the AER should retain a 
sample of the product, especially if the adverse event is 
serious, in case testing for adulteration or contamination 
is indicated. It is especially important for quality docu-
mentation of herbal product AERs as there are many types 
of herbs and preparations available. Improved surveil-
lance and comprehensive reporting are necessary for pro-
viders and caregivers to make informed decisions about 
recommending herbal products to children. 
In our review, an important finding is the high rep-
resentation of unintentional ingestions (36%). As with 
drugs, herbal exposures can be unintentional in nature, 
either as the result of misuse by a parent or poor supervi-
sion of the child. A study by Gryzlak et al examined poi-
son control center reports from 64 centers across the 
United States and focused specifically on two of the most 
widely used herbs, echinacea and St John’s wort. They 
found that the majority of exposures for both herbs were 
in children under the age of 5 years and noted that many 
exposures were coded as unintentional.27 A high percent-
age of unintentional ingestions could affect evaluation of 
toxicity and treatment. For example, these products may 
be less likely to go through evaluation in clinical trials. 
The US Consumer Product Safety Commission 
requires that oral prescription drugs for children be dis-
table 2 Adherence Criteria of Adverse Events Case Reports Based on the International Society of Epidemiology’s “Guidelines for Submit-
ting Adverse Event Reports for Publication”4
Item description point Value cases With Item present (%)
demographics Age 1 127 (99)
Sex 1 110 (86)
current health status Disease or symptoms being treated with suspect herb 1 115 (90)
medical history Medical history relevant to adverse event 1 101 (79)
physical examination Abnormal physical or laboratory findings 1 121 (95)
patient disposition Presence or absence of death, life-threatening circumstances,  
hospitalization or prolonged hospitalization, or significant disability 
1 127 (99)
herb information Latin binomial name of herb ingredients 1 66 (52)
Generic name vs proprietary name of herb 1 113 (88)
Plant part(s) 1 52 (41)
Type of preparation: crude herb or extract 1 120 (94)
Manufacturer: producer of herb 1 26 (20)
dosage Dosage: approximate amount of herb 1 76 (59)
Duration of therapy: how long herb has been taken 1 118 (92)
duration of herb use  
before adverse event
Therapy duration before adverse event and its interface with  
the adverse event 1 52 (44)
concomitant therapies Assessment of potential contribution of concomitant therapies 1 28 (22)
description of adverse 
event
Description of adverse event and its severity compared with estab-
lished definitions and outcome of adverse event 1 127 (99)
discussion Presence or absence of evidence supporting causal link including 
timing, dechallenge, and rechallenge (or state why these were  
not possible) 
Discussion of previous reports of adverse event in biomedical  
journal or product labeling 
1 119 (93)
total points achievable 17
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table 3 Adverse Event Reports With Adherence Scores of 15 or Greater
reference  
(author, Year) 
adherence 
score 
herb common Name 
(Latin name)
age of 
child
adverse Event route of administration  
or Exposure 
Outcome
Panis et al,
20055
17 Fleeceflower root 
(Polygonum multiflorum)
5 y Acute toxic hepatitis Intentionally ingested  
tablets adulterated with 
anthraquinones
Resolution of symptoms
Humberston et al,
20036
16 Kava kava  
(Piper methysticum)
14 y Acute hepatitis Intentional ingestion Liver transplant 
Morris et al,
20037
16 Tea tree  
(Melaleuca alternifolia)
4 y Ataxia,  
unresponsiveness 
Unintentional ingestion Resolution of symptoms 
Koren et al,
19908
16 Ginseng  
(Ginseng siberian)
1 d Neonatal hirsutism, 
androgenous effects
Mother took ginseng while 
pregnant and breastfeeding 
for 2 wk
Resolution of symptoms 
Jones et al,
19989
16 Blue cohosh  
(Caulophyllum thalictroides)
1 d Neonatal congestive 
heart failure
Mother used blue cohosh 
tablets 1 mo prior to deliv-
ery to induce delivery 
Hospitalization in neonatal 
intensive care unit, at 2-y 
follow-up cardiomegaly 
present and patient receiv-
ing digoxin 
Chan et al,
200710
15 Pearl powder (traditional 
herbal medicine formula)
9 d Cyanosis with  
methemoglobinemia
Intentional ingestion admin-
istered for poor feeding
Resolution of symptoms
Henley et al,
200711
15 Tea tree  
(Melaleuca alternifolia)
10 y Gynecomastia Topically applied to hair 
with lavender (Lavendula 
augustifolia)
Resolution of symptoms
Martin et al,
200712
15 Yerba de mate  
(Ilex paraguariensis)
1 d Neonatal  
withdrawal
Mother drank mate  
during pregnancy
Reduction of symptoms
Rafaat et al,
200013
15 Garlic (Allium sativum) 3 mo Blisters, lesions, and 
third degree burns
Garlic bulbs applied to  
feet and ankles
Wounds healed
Garty et al,
199314
15 Garlic (Allium sativum) 6 mo Ulceration and 
lesion 
Crushed garlic cloves  
fixed to wrists
Wounds healed
Darben et al, 
199815
15 Eucalyptus  
(Eucalyptus globulus)
6 y Ataxia, weakness, 
unconsciousness
Topically applied bandages 
soaked with eucalyptus
Resolution of symptoms
Bagheri et al, 
199816
15 Valerian, ballote,  
hawthorn, passiflora, kola 
(Valeriana officinalis, 
Ballota nigra, Crataegus 
oxyacantha, Passiflora 
incarnata, Cola nitida)
13 y Acute hepatitis Intentional ingestion of  
pill for anxiety 
Liver transplant
Schmid et al,
200617
15 Broom bush  
(Retama raetam)
7 d Respiratory failure Intentional ingestion of tea Hospitalization in pediatric 
intensive care unit, resolu-
tion of symptoms 
Bhowmick et al,
200718
15 Goldenseal  
(Hydrastis canadensis)
11 y Diabetic ketoacido-
sis, hypernatremia, 
hyperosmolality 
Intentional ingestion of  
tablets for polyuria
Discharged with  
instructions to discontinue 
goldenseal 
Asiri et al,
200619
15 Myrrh, mahaleb, anise, 
hauwa (Commiphora 
molmol, Prunus mahaleb, 
Pimpinella anisum, 
Launaea capitata)
10 mo Lead toxicity Herbs pasted to gums  
for teething
Death of infant 
Corazza et al,
200720
15 Tea tree  
(Melaleuca alternifolia)
16 y Acute vulvitis Oil applied as a kolorex 
cream with pepper tree 
(Pseudowintera colorata)
Resolution of symptoms 
Florkowski et al, 
200221
15 Multi-ingredient with  
yellow powder and snake 
extract
10 y Adrenal suppression Intentional ingestion of  
capsule for asthma and 
eczema
Resolution of symptoms
Roulet et al,
198822
15 Herbal tea 5 d Hepatic vaso- 
occlusive disease 
Herbal tea containing pyrro-
lidizine alkaloids consumed 
through pregnancy
Death of infant 
Khandpur et al, 
200823
15 Ayurvedic products 11 y Hypo- and hyperpig-
mented macules all 
over body, thickening 
of palms and soles, 
abdominal pain
Pills and powders intention-
ally ingested, products con-
taminated with arsenic
Resolution of symptoms
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pensed in child-resistant packaging unless the drug is 
exempted or the patient or prescriber requests otherwise. 
The only dietary supplement with a special packaging 
requirement is iron-containing drugs and dietary supple-
ments that contain 250 mg or more of elemental iron.28 
We also found that some exposures occurred because an 
herbal product was administered in a manner contradict-
ing its traditional intended use. For example, while the 
product is beneficial if topically applied, it may cause a 
negative reaction if ingested (eg, aloe). It also indicates 
the need for careful labeling of herbal products, clear 
instructions for use, and monitoring of use. 
Our adherence rubric was based on the ISE’s 
“Guidelines for Submitting Adverse Events Reports for 
Publication.”4 Only one case report contained all the 
necessary components of a comprehensive AER accord-
ing to the most basic guidelines. The most commonly 
missed items were information about the herbal prod-
uct and the use of any concomitant therapies that could 
have interacted with the herb. While there were no 
correlations between adherence score and characteris-
tics of the journal (year of publication or adult vs pedi-
atric journal), there is considerable room for improve-
ment in reporting AEs. 
Research suggests that reporting of AEs in case 
reports has improved over the last decade.29 Ideally, an 
AER would contain the most accurate and complete 
information available about the episode. However, one 
could argue that certain components of the AER may be 
more important than others. Many of the reports con-
tained a wealth of information but failed to discuss dura-
tion of therapy or the presence or absence of concomitant 
therapies. This could be problematic as there is no way of 
assessing whether an interaction between therapies 
could have occurred. 
There are many limitations in our study. First, we 
only assessed published case reports. There is a great need 
for comprehensive reporting to poison control centers, 
MedWatch, and other types of journals. The medical lit-
erature only has a fraction of all AEs related to herb use. 
Research has indicated that literature searches for adverse 
events can be particularly difficult as it requires careful 
coding and indexing of information.30,31 Thus, there 
could be missing AERs that we were unable to capture in 
our searches. We also did not include case reports where 
herbs were used as recreational drugs, thus underestimat-
ing the true number of AEs in the literature. We only 
included English language case reports and thus did not 
address whether non-English case reports show similar 
trends in documentation and types of AEs. We also lim-
ited our search to children under 18 years old and there-
fore did not address AEs from herbal sport supplements 
that are often used by college-age and older adolescents.
Our adherence scores contained information 
deemed necessary by ISE guidelines that described herbal 
products. These guidelines have not been tested exten-
sively, which limits previous research involving these 
guidelines and thus limits corroboration with our adher-
ence score. There have been other guidelines regarding 
the reporting of AEs; however, the ISE guidelines include 
information specific to herbal products.32,33 Lastly, for 
products unintentionally ingested by the child, it may 
not be possible for the AER to include information about 
duration of treatment and symptoms related to the use as 
it is an unintentional ingestion. 
cONcLUsION
Our research suggests that there is need for 
improvement in reporting of AEs in case reports. 
While there are no standardized guidelines for all 
medical journals for case reports, our systematic review 
provides a starting point for future discussions about 
appropriate documentation for AERs. The goal is to 
establish high-quality case reports that provide the 
most comprehensive information about the products 
(eg, dietary supplements, medications) and the case 
history so that causality can be evaluated. Parents and 
health practitioners need to be aware of the risks and 
benefits of herbal supplements. Information about 
risks would be improved with more complete informa-
tion of AEs in published case reports. 
appendix 1 Search Terms Used for 
Systematic Review
Search terms used or variations thereof depending on the data-
base searched: 
herbs/natural herbal products
Spermatophyta; herbal drugs; herbal teas; medicinal plants; 
plant extracts; traditional medicines; medicinal properties; 
medicinal fungi; ethnobotany; phytotherapy; medicinal plants; 
herbal medicine; plant extracts; ethnopharmacology; medicinal 
herb; herbal medicine; plant oils; herbal remedy; medicinal 
fungi; officinal plants
pediatric 
Children; adolescents; infants; young adults; youth (infant or 
infancy or newborn or baby or babies or neonate or preterm or 
premature or postmature), (child or schoolchild or school age or 
preschool or kid or kids or toddler), (puberty or pubescent or pre-
pubescent); (paediatric or pediatric or peadiatric), (nursery school$ 
or kindergarten or primary school or secondary school or elemen-
tary school or high school$ or highschool), (adolescent or girl or 
boy or teen); fetus/ or fetal development/ or fetal growth; mater-
nal transmission; prenatal; pregnany; gestation (foetal or fetal)
case reports
case reports/ or case studies/ or research/ or trials; case report; 
case study (case adj3 report), (case adj3 study); spontaneous 
report (anecdotal adj3 report), (anecdotal adj3 stud$); postmar-
keting surveillance; post-marketing surveillance
safety
1. risk/
2. safety/ or food safety/
3. exp poisoning/
4. (adverse adj3 [event or effect]); side effect; toxicity; (tolerabili-
ty or tolerance or well tolerated); (adr or adrs or ade or ades); 
unanticipated event; unanticipated effect; unwanted event; 
unwanted effect; toxic effect; ([lead or mercury or heavy metal 
or cadmium or plant or manganese] adj3 poisoning); drug  
toxicity; (adverse adj3 reaction); herb-drug interactions/
Depending on the database being searched, one or both of 
the case reports and safety searches were included or some-
times combined. 
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